Literature DB >> 2974926

Human calpactin II (lipocortin I) messenger ribonucleic acid is not induced by glucocorticoids.

M Brönnegård1, O Andersson, D Edwall, J Lund, G Norstedt, J Carstedt-Duke.   

Abstract

Studies were carried out to examine the effect of glucocorticoids on human calpactin II (lipocortin I) mRNA expression. A cRNA probe for human calpactin II (hCPII) was used in a solution hybridization assay to study the effect of dexamethasone on hCPII mRNA levels in human skin fibroblasts, peripheral lymphocytes, pulmonary alveolar macrophages, and HeLa S3 cells. As a positive control, human metallothionein II (hMTII) mRNA levels were measured since hMTII is known to be regulated by glucocorticoids and heavy metals, both of which induce transcriptional activity of the gene. Dexamethasone treatment of these human cell types caused a dose-dependent increase in hMTII mRNA levels, whereas no effect on hCPII mRNA levels was observed. These findings were confirmed in time course studies, where 10(-6) M dexamethasone treatment caused a maximal 2- to 5-fold increase in hMTII mRNA levels after 6-8 h of treatment but no increase in hCPII mRNA levels was observed at any time point up to 24 h. A human glucocorticoid sensitive lymphoid cell line, CEM C7, and a glucocorticoid resistant mutant, ICR-27, isolated from CEM C7, were included in order to confirm the requirement of a functional glucocorticoid receptor (GR) in the induction of glucocorticoid-regulated genes. Dexamethasone (10(-6) M) induced hMTII but not hCPII mRNA in CEM C7 cells, whereas neither hMTII nor hCPII mRNA was induced in ICR-27 cells. In conclusion, our data suggest that glucocorticoids do not induce calpactin II (lipocortin I) mRNA in the human cell types studied.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974926     DOI: 10.1210/mend-2-8-732

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  10 in total

1.  Synthesis of p36 and p35 is increased when U-937 cells differentiate in culture but expression is not inducible by glucocorticoids.

Authors:  C M Isacke; R A Lindberg; T Hunter
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

2.  Beta-adrenoceptor expression in human fat cells from different regions.

Authors:  P Arner; L Hellström; H Wahrenberg; M Brönnegård
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.

Authors:  J L Masferrer; B S Zweifel; K Seibert; P Needleman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

4.  Expression of annexins as a function of cellular growth state.

Authors:  D D Schlaepfer; H T Haigler
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

5.  Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines.

Authors:  L Danel-Moore; M Brönnegard; J A Gustafsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

6.  Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases.

Authors:  A Raz; A Wyche; P Needleman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Expression of human recombinant lipocortin I in a wheat-germ cell-free system and Xenopus oocytes. Lipocortin is not secreted.

Authors:  B M Frey; F J Frey; V R Lingappa; H Trachsel
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

8.  Protein-synthesis-dependent induction of annexin I by glucocorticoid.

Authors:  W T Wong; S C Frost; H S Nick
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

9.  Translocation of lipocortin (annexin) 1 to the membrane of U937 cells induced by phorbol ester, but not by dexamethasone.

Authors:  S A Kang; Y J Cho; H B Moon; D S Na
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain.

Authors:  J K Relton; P J Strijbos; C T O'Shaughnessy; F Carey; R A Forder; F J Tilders; N J Rothwell
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.